<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237729</url>
  </required_header>
  <id_info>
    <org_study_id>B5381007</org_study_id>
    <secondary_id>REFLECTIONS B538-07</secondary_id>
    <nct_id>NCT02237729</nct_id>
  </id_info>
  <brief_title>A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))</brief_title>
  <acronym>B538-07</acronym>
  <official_title>Phase 1, Double Blind, Randomized, Parallel-group, 3-arm, Single-dose, Comparative Pharmacokinetic Study Of Pf-06410293 and Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm,
      single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and
      EU administered subcutaneously (SC) to healthy male and female volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal serum concentration (Cmax)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>maximal serum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration time curve (AUC) from time 0 to 2 weeks (AUC0-2wk)</measure>
    <time_frame>0-336 hours</time_frame>
    <description>area under the concentration time curve (AUC) from time 0 to 336 hours (AUC0-2wk)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-T)]</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>AUC (0-T)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-T)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC extrapolated to infinity (AUC0inf)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>AUC extrapolated to infinity (AUC0inf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events, and abnormalities in laboratory parameters</measure>
    <time_frame>Day 1- Day 71</time_frame>
    <description>Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events, and abnormalities in laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antidrug antibodies (ADA) and neutralizing antibodies (NAb)</measure>
    <time_frame>Day 1- Day 71</time_frame>
    <description>Incidence of antidrug antibodies (ADA) and neutralizing antibodies (NAb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximal serum concentration (Cmax) for adalimumab EU as compared to adalimumab US</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>maximal serum concentration (Cmax) for adalimumab EU as compared to adalimumab US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration time curve (AUC) from time 0 to 2 weeks (AUC0-2wk) for adalimumab EU as compared to adalimumab US</measure>
    <time_frame>0-336 hours</time_frame>
    <description>area under the concentration time curve (AUC) from time 0 to 336 hours (AUC0-2wk) for adalimumab EU as compared to adalimumab US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-T)] for adalimumab EU as compared to adalimumab US</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>AUC (0-T)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-T) for adalimumab EU as compared to adalimumab US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC extrapolated to infinity (AUC0inf) for adalimumab EU as compared to adalimumab US</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>AUC extrapolated to infinity (AUC0inf) for adalimumab EU as compared to adalimumab US</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach the maximum concentration (Tmax)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>time to reach the maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>Apparent clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>Apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (T1/2)</measure>
    <time_frame>Day 1 - Day 50</time_frame>
    <description>Terminal half-life (T1/2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>PF-06410293</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab-US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab-EU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06410293</intervention_name>
    <description>PF-06410293 will be administered as a single 40 mg, subcutaneous dose</description>
    <arm_group_label>PF-06410293</arm_group_label>
    <other_name>Adalimumab-Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab-US</intervention_name>
    <description>Adalimumab-US will be administered as a single 40 mg, subcutaneous dose</description>
    <arm_group_label>Adalimumab-US</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab-EU</intervention_name>
    <description>Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose</description>
    <arm_group_label>Adalimumab-EU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects between the ages of 18 and 45 years, inclusive.
             Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, complete physical examination including blood pressure and heart rate
             measurement, 12 lead ECG and clinical laboratory tests.

          -  Body Mass Index (BMI) of 19.0 to 30.5 kg/m2; and a total body weight &gt;60 kg (132 lbs).

          -  Chest X ray with no evidence of current, active TB or previous (inactive) TB, general
             infections, heart failure, malignancy, or other clinically significant abnormalities
             taken at Screening or within 24 weeks prior to Day 1 and read by a qualified
             radiologist.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,
             autoimmune, or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at the time of dosing).

          -  Previous history of cancer, except for adequately treated basal cell or squamous cell
             carcinoma of the skin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>De La Pedraja Radiology Associates</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeaView Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeaView Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeaView Reseach Screening Office</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeaView Research, Inc. (Screening Office)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research, LLC</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5381007&amp;StudyName=A%20Study%20Of%20PF-06410293%20%28Adalimumab-Pfizer%29%20And%20Adalimumab%20%28Humira%29%20In%20Healthy%20Subjects%20%28REFLECTIONS%20B538-07%29%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <keyword>immunology</keyword>
  <keyword>PK</keyword>
  <keyword>Phase 1</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>biosimilarity</keyword>
  <keyword>adalimumab</keyword>
  <keyword>single dose.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

